Zhu, McClure, Harrison, Genco and Massari (2019) applied a reverse-vaccinology-like Candidate Antigen Selection Strategy (CASS) to gonococcal hypothetical proteins expressed during natural human mucosal infection and identified six conserved candidates (NGO0416, NGO0690, NGO0948/BamC, NGO1043, NGO1215, NGO1701); the paper's Discussion raised unresolved issues bearing on whether such antigens can advance toward clinical development: in-vivo protective efficacy, mechanistic roles and essentiality, impact of allelic diversity on antibody recognition, cross-reactivity safety toward commensal Neisseria, adjuvant optimization beyond the alum-induced Th2 skew, physiological surface exposure, and the absence of known correlates of protection. The 2020-2026 follow-up literature documents resolution of three specific preclinical strands: a trivalent NGO0690+NGO0948+NGO1701 vaccine adjuvanted with alum plus MPLA (monophosphoryl lipid A, an adjuvant that shifts responses toward Th1) accelerates bacterial clearance in the mouse vaginal-infection model, NGO1701 was functionally identified as a periplasmic copper storage protein (Csp) with deletion-mutant validation of its serological relevance, and balanced Th1/Th2 responses were achieved preclinically. The surviving open core is translational: in-vivo efficacy beyond accelerated vaginal-colonization clearance in female mice (transmission and male genitourinary infection remain untested), functional characterization of the remaining candidates, understanding how allele polymorphisms affect antibody recognition and functional activity, direct experimental verification that vaccine-induced immunity does not target commensal Neisseria lactamica, adjuvant and delivery optimization toward Th1-favoring immunity together with clarified physiological surface exposure, and - field-wide - validated human correlates of protective immunity, a gap sharpened by two 2026 randomized trials in which 4CMenB raised serum bactericidal titers without significantly protecting against gonorrhea.

Background

Neisseria gonorrhoeae is a sexually transmitted bacterium with more than 80 million estimated annual cases worldwide and steadily spreading antimicrobial resistance, and no licensed vaccine exists. Two long-standing obstacles shape gonococcal vaccinology: the bacterium varies or masks most exposed surface antigens, and there is no validated correlate of protection, i.e., no measurable immune quantity that predicts whether a vaccinated person is protected, so vaccine evaluation relies on animal models and indirect in-vitro readouts. The main in-vitro functional readout is serum bactericidal activity (SBA), the dilution at which antibodies plus complement kill bacteria in serum. Evidence that an outer-membrane-vesicle (OMV) meningococcal vaccine (MeNZB; OMVs are shed bacterial membrane blebs used as vaccine material) partially reduced gonorrhea incidence in observational studies revived interest in cross-reactive OMV antigens, now formulated as the licensed 4CMenB (Bexsero) vaccine. In parallel, reverse vaccinology - selecting antigens by genome and bioinformatic filtering rather than by empirical immunogenicity - was extended to gonococci. Zhu et al. (2019) designed CASS, the Candidate Antigen Selection Strategy, which mined gonococcal hypothetical proteins (predicted proteins of unknown function) whose genes are expressed during natural human mucosal infection, ranked by predicted immunogenicity, membrane association, conservation, and amenability to recombinant expression. From 36 predicted targets they produced six recombinant proteins (locus tags NGO0416, NGO0690, NGO0948 - later identified as the homolog of BamC, a lipoprotein component of the beta-barrel assembly machinery complex that inserts proteins into the bacterial outer membrane - NGO1043, NGO1215, and NGO1701). All six were conserved core-genome loci with limited allelic variability; immunization of mice with each protein in alum (an aluminium-salt adjuvant that biases toward Th2-type antibody-skewed immunity, whereas Th1 and Th17 effector T-cell responses - T-helper type 1 and type 17 - promote inflammatory and mucosal clearance mechanisms that accelerate gonococcal clearance in models) elicited antibodies with cross-strain serum bactericidal activity. The authors noted a discrepancy between reactivity of outer-membrane-protein fractions and whole-bacteria FACS (flow cytometry, here used to detect antibody binding to the intact bacterial surface), leaving surface accessibility uncertain - relevant because periplasmic proteins (located between the inner and outer membranes) may still reach the surface partially or via OMVs, as occurs in Bexsero. Sequence analysis against the commensal bacterium Neisseria lactamica, which colonizes the nasopharynx and may contribute beneficial natural immunity, showed limited identity only, but no direct cross-reactivity testing was performed. The paper's Discussion raised the follow-up analyses needed before a CASS antigen could move toward clinical development.

Problem Statement

Can the CASS-identified gonococcal antigens (NGO0416, NGO0690, NGO0948/BamC, NGO1043, NGO1215, NGO1701/Csp) be advanced from mouse-colonization protection toward a clinically viable gonorrhea vaccine by resolving the specific issues that the 2019 source's Discussion raised and that remain open after the 2020-2026 follow-up literature: (1) in-vivo protective efficacy - the source stated that analyses of protective responses in a mouse model of gonococcal infection were ongoing; follow-up work has shown accelerated clearance in the female mouse vaginal-colonization model, while efficacy against transmission and in male genitourinary infection remains untested; (2) mechanistic roles and essentiality of the remaining candidates (NGO0416, NGO1043, NGO1215, and the still-unassigned function of NGO0690), for which the source reported deletion-mutant construction as ongoing; (3) how natural allelic polymorphisms across gonococcal strains affect antibody recognition and functional activity (serum bactericidal activity; opsonophagocytosis, i.e. antibody-mediated phagocytic uptake and killing of bacteria) - the source reported per-locus allele frequencies but did not experimentally link sequence variation to recognition or killing; (4) direct experimental verification that vaccine-induced immunity does not undesirably target beneficial commensal Neisseria (N. lactamica), for which the source performed sequence comparison only, without cross-reactivity testing (similarity to human proteins was a bioinformatic CASS exclusion attribute rather than an experimentally tested safety claim); (5) optimization of adjuvants and delivery beyond the parenteral alum-induced Th2 profile - the source suggested that a Th1 component may be advantageous and could be exploited using different adjuvants, possibly mucosal - together with clarification of each antigen's localization and surface accessibility under in vivo-like physiological conditions (in situ expression and OMV incorporation), the outer-membrane-fraction-versus-whole-bacteria discrepancy the 2019 study left unresolved; and (6) validated human correlate(s) of protective immunity that translate in-vitro readouts such as serum bactericidal activity into predicted clinical protection, which the source noted are unknown - a field-wide gap made more pressing by 2026 randomized trials showing bactericidal-titer rises without significant protection.

References

  1. Zhu T, McClure R, Harrison OB, Genco C, Massari P. Integrated Bioinformatic Analyses and Immune Characterization of New Neisseria gonorrhoeae Vaccine Antigens Expressed during Natural Mucosal Infection. Vaccines 7(4):153, 2019. doi:10.3390/vaccines7040153. https://doi.org/10.3390/vaccines7040153
  2. Roe SK, Felter B, Zheng B, Ram S, Wetzler LM, Garges E, Zhu T, Genco CA, Massari P. In Vitro Pre-Clinical Evaluation of a Gonococcal Trivalent Candidate Vaccine Identified by Transcriptomics. Vaccines 11(12):1846, 2023. doi:10.3390/vaccines11121846. https://doi.org/10.3390/vaccines11121846
  3. Roe SK, Mazgaj R, Zhu T, Esmaeeli M, Lewis LA, Genco C, Waldron KJ, Massari P. The gonococcal vaccine candidate antigen NGO1701 is a N. gonorrhoeae periplasmic copper storage protein. PLOS Pathogens 21(10):e1013559, 2025. doi:10.1371/journal.ppat.1013559. https://doi.org/10.1371/journal.ppat.1013559
  4. Roe SK, Zheng B, Gulati S, Genco C, Ram S, Massari P. Preclinical in vivo evaluation of a gonococcal multivalent vaccine containing antigens identified by CASS. Frontiers in Immunology 16:1688536, 2025. doi:10.3389/fimmu.2025.1688536. https://doi.org/10.3389/fimmu.2025.1688536
  5. Williams E, Seib KL, Fairley CK, Pollock GL, Hocking JS, McCarthy JS, Williamson DA. Neisseria gonorrhoeae vaccines: a contemporary overview. Clinical Microbiology Reviews 37(1):e00094-23, 2024. doi:10.1128/cmr.00094-23. https://doi.org/10.1128/cmr.00094-23
  6. Stejskal L, Thistlethwaite A, Ramirez-Bencomo F, Rashmi S, Harrison O, Feavers IM, Maiden MCJ, Jerse A, Barnes G, Chirro O, Chemweno J, Nduati E, Cehovin A, Tang C, Sanders EJ, Derrick JP. Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population. Nature Communications 15:6712, 2024. doi:10.1038/s41467-024-51053-x. https://doi.org/10.1038/s41467-024-51053-x
  7. Seib KL, Donovan B, Jin F, Thng C, Yeung B, Comninos N, Bopage RI, Ray A, Mahony A, Chow EPF, Chen MY, Maddaford K, Lau H, Westall P, Lu D, Bavinton BR, Petoumenos K, Whiley DM, Jennings MP, Jennison AV, Kaldor J, Guy R, Lahra MM, Costello J, Mackie B, Templeton DJ, Eu B, O'Reilly M, Fairley CK, McNulty A, Varma R, Lewis DA, Grulich AE. Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection (GoGoVax randomized trial). New England Journal of Medicine 395:349-361, 2026. doi:10.1056/NEJMoa2516739. https://doi.org/10.1056/NEJMoa2516739
  8. Thng C, Eskandari S, Jin F, Hughes I, Grulich AE, O'Sullivan M, Semchenko EA, Seib KL. Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO). npj Vaccines 11:162, 2026. doi:10.1038/s41541-026-01422-y. https://doi.org/10.1038/s41541-026-01422-y
  9. McKeand SA, Ramirez Bencomo F, Soc A, Jones RA, Thistlethwaite A, Gu Z, Nduati E, Sanders EJ, Jerse AE, Derrick JP, Tang CM. Investigation of Correlates of Protection Against Gonococcal Infection by Comparative Immunoprofiling of Responses in Experimental and Clinical Studies. Journal of Infectious Diseases 233(6):e1443-e1453, 2026. doi:10.1093/infdis/jiag216. https://doi.org/10.1093/infdis/jiag216
  10. Lu Q, Yang H, Peng Y, Dong Z, Nie P, Wang G, Luo S, Min X, Huang J, Huang M. Intranasal trivalent candidate vaccine induces strong mucosal and systemic immune responses against Neisseria gonorrhoeae. Frontiers in Immunology 15:1473193, 2024. doi:10.3389/fimmu.2024.1473193. https://doi.org/10.3389/fimmu.2024.1473193
  11. Yakobi SH, Nwodo UU. Immunoinformatics-Based Design of a Multi-Epitope Vaccine Targeting a Conserved Copper-Associated Protein in Neisseria gonorrhoeae. Biotechnology and Applied Biochemistry, 2026. doi:10.1002/bab.70179. https://doi.org/10.1002/bab.70179
  12. MacLennan CA, Davis P, Gottlieb SL, Seib KL, Harrison OB, Duncan JA, Gorringe A, Criss AK, Jerse A, Russell MW, Isbrucker R, Kaminski RW, Connolly K, Vipond C, Belcher T, Campbell H, Delany-Moretlwe S, Finco O, Wilson S, Vichos I, Rhyne P, Pizza M, Deal C, Bash MC, Stickings P. Consultation report - gonococcal immunoassays and standards for vaccine development. Vaccine 86:128694, 2026. doi:10.1016/j.vaccine.2026.128694. https://doi.org/10.1016/j.vaccine.2026.128694